Table 5.
Outcomes in dCBT versus sCBT according to cell dose in multivariate analyses (adjusted for patient age, disease status, ALL versus AML, conditioning regimen, cytogenetic risk, and ATG)
| Hazard ratio | 95% confidence interval | P value | ||
|---|---|---|---|---|
| Lower limit | Upper limit | |||
| Relapse | ||||
| sCBT and TNC > median (ref) | – | – | – | – |
| dCBT and TNC > median | 1.32 | 0.67 | 2.58 | 0.42 |
| sCBT and TNC < median | 1.99 | 1.02 | 3.89 | 0.04 |
| dCBT and TNC < median | 1.74 | 0.88 | 3.43 | 0.11 |
| Nonrelapse mortality | ||||
| sCBT and TNC > median (ref) | – | – | – | – |
| dCBT and TNC > median | 0.69 | 0.35 | 1.36 | 0.29 |
| sCBT and TNC < median | 1.01 | 0.53 | 1.93 | 0.97 |
| dCBT and TNC < median | 0.93 | 0.47 | 1.83 | 0.84 |
| Leukemia-free survival | ||||
| sCBT and TNC > median (ref) | – | – | – | – |
| dCBT and TNC > median | 0.97 | 0.61 | 1.55 | 0.89 |
| sCBT and TNC < median | 1.46 | 0.92 | 2.30 | 0.11 |
| dCBT and TNC < median | 1.27 | 0.79 | 2.03 | 0.33 |
| Overall survival | ||||
| sCBT and TNC > median (ref) | – | – | – | – |
| dCBT and TNC > median | 0.97 | 0.60 | 1.58 | 0.91 |
| sCBT and TNC < median | 1.39 | 0.86 | 2.23 | 0.18 |
| dCBT and TNC < median | 1.07 | 0.65 | 1.77 | 0.78 |